Latest news
Ignyte Group Selects Begić to Lead West Coast Work - GovTechGovTech · Fri, 07 Aug 2026 01:38:48 GMTReplimune wins on third try as FDA clears Tudriqev for melanoma - FirstWord PharmaFirstWord Pharma · Fri, 07 Aug 2026 00:57:10 GMTFDA Advisory Committee Backs RP1 for Advanced Melanoma - Cure TodayCure Today · Sun, 02 Aug 2026 14:37:01 GMTStephanie Kauffman: Awaiting the FDA's Final Decision on the IGNYTE Trial for Advanced Melanoma - OncodailyOncodaily · Sun, 02 Aug 2026 09:26:49 GMTFDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study - pharmexec.compharmexec.com · Fri, 31 Jul 2026 07:00:00 GMTReplimune advisory panel finds IGNYTE efficacy results evaluable and clinically meaningful - TradingViewTradingView · Fri, 31 Jul 2026 07:00:00 GMTReplimune’s twice-rejected melanoma drug prevails in FDA adcomm - Fierce BiotechFierce Biotech · Thu, 30 Jul 2026 22:20:27 GMTReplimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review (REPL) - Seeking AlphaSeeking Alpha · Thu, 30 Jul 2026 07:00:00 GMT